Eating Habits and Behavior in People Affected by Lipodystrophy: Observational Study (lipo-diet_2024)
Title: Dietary Habits and Eating Behavior in People with Lipodystrophy: An Observational Study.
Purpose: The purpose of this study is to investigate and analyze the dietary habits and eating behaviors of patients diagnosed with lipodystrophy. Since there is currently a lack of specific data on how these patients approach nutrition, this research aims to provide essential information to improve nutritional guidelines. Additionally, the study seeks to understand if there is a relationship between eating behaviors and the patients' clinical data, such as blood test results and body measurements (anthropometric parameters).
Study Design:
This is an observational, cross-sectional, single-center study with a 2-year enrollment period. Participants will be recruited during their regular medical visits at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.
During the study, the following activities will take place:
Clinical Data Collection: Researchers will record body measurements and blood test results as part of standard clinical practice.
Questionnaires: Patients will be asked to complete four specific questionnaires (available in Italian and English) regarding their food frequency, eating behavior patterns, tendencies toward orthorexia, and physical activity levels.
Format: These questionnaires can be completed electronically via a RedCap link (taking approximately 20-30 minutes) or on paper.
Eligibility:
Inclusion Criteria: Adults (18 years or older) with a confirmed diagnosis of lipodystrophy who provide informed consent.
Exclusion Criteria: Patients with HIV-related lipodystrophy or those who cannot understand the languages in which the questionnaires are provided.
Duration and Participation:
The study will last a total of 2 years and 6 months. The first 2 years are dedicated to patient selection and recruitment, followed by 6 months for data analysis. The researchers aim to enroll 30 participants.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
1. Background and RationaleLipodystrophy refers to a rare and heterogeneous group of syndromes characterized by the total or partial loss of subcutaneous adipose tissue. This condition leads to severe metabolic complications, such as marked insulin resistance, early-onset diabetes, severe hypertriglyceridemia, and hepatic steatosis (fatty liver).A key factor in this pathology is hypoleptinemia (deficiency of the hormone leptin), which plays a crucial role in regulating energy balance. The lack of leptin disrupts satiety signals, often resulting in hyperphagia (insatiable hunger), with energy intake potentially exceeding requirements by up to 40%. While lifestyle and dietary modifications are considered the "cornerstone" of treatment, there is currently a significant lack of structured data and evidence-based nutritional guidelines for these patients.2. Study ObjectivesPrimary Objective: To identify, analyze, and describe the lifestyle of patients with a focus on dietary habits, eating behaviors, and physical activity.Secondary Objective: To explore the relationship between these behaviors and clinical data, including anthropometric measurements and biochemical (blood) parameters.3. Study Population and EligibilityThe study aims to enroll 30 patients managed at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.Inclusion Criteria: Male and female adults (≥ 18 years old) with a confirmed diagnosis of lipodystrophy who provide written informed consent.Exclusion Criteria: Patients with HIV-related lipodystrophy or those unable to understand the languages in which the questionnaires are provided.4. Study Design and MethodologyThis is a prospective, cross-sectional, observational, single-center study. Data will be collected during routine endocrinological visits through the following means:A. Clinical and Biochemical ParametersAnthropometric Data: Weight, height, BMI, waist and hip circumference, and body fat percentage.Biochemical Data: Fasting plasma glucose, HbA1c, full lipid profile (total cholesterol, HDL, LDL, triglycerides), liver enzymes (AST, ALT), kidney function, insulin levels, and HOMA-IR.B. Self-Assessment QuestionnairesParticipants will complete four validated tools (estimated time: 30 minutes, via RedCap or paper):Food Frequency Questionnaire (FFQ): To assess the intake frequency of 36 food items over the past 12 months.Three-Factor Eating Questionnaire (TFEQ-R18): To evaluate cognitive restraint, uncontrolled eating, and emotional eating.Teruel Orthorexia Scale (TOS): To measure orthorexic tendencies (obsession with healthy eating) in both "healthy" and "nervosa" dimensions.IPAQ-Short Form: To categorize physical activity levels as low, moderate, or high.5. Study Duration and AnalysisThe total study duration is 2 years and 6 months. This includes 2 years for patient recruitment and 6 months for data analysis. Statistical analysis will be performed using STATA 19 SE, comparing the observed dietary data with the 2024 LARN guidelines (Nutrient and Energy Reference Intake Levels) to identify deviations and correlations with metabolic health.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carolina Poli, nutritionist
- Phone Number: 0512094676
- Email: carolina.poli@aosp.bo.it
Study Locations
-
-
Bologna
-
Bologna, Bologna, Italy, 40138
- Recruiting
- IRCSS Azienda Ospedaliero-Universitaria di Bologna
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Male and female patients over the age of 18 attending the outpatient service of the Endocrinology and Diabetes Prevention and Treatment Unit - U. Pagotto - IRCCS AOU in Bologna, Policlinico Sant'Orsola - Malpighi during their visit to the dedicated clinic.
Description
Inclusion Criteria:
- Obtaining informed consent
- Age 18 or older at the time of diagnosis
- Diagnosis of lipodystrophy
Exclusion Criteria:
- Failure to understand the language in which the questionnaires are administered
- HIV-related lipodystrophy
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Food Frequency Questionnaire (FFQ)
Time Frame: baseline
|
baseline
|
|
|
Three-Factor Eating Questionnaire R-18 (TFEQ-R18)
Time Frame: baseline
|
Assessment of eating behavior using the 18-item validated questionnaire, evaluating three subscales: Cognitive Restraint (CR), Uncontrolled Eating (UE), and Emotional Eating (EE). Items are scored on a 4-point scale and converted to a 0-100 scale per domain, where higher scores indicate higher expression of the specific behavior. |
baseline
|
|
Teruel Orthorexia Scale (TOS)
Time Frame: baseline
|
baseline
|
|
|
International Physical Activity Questionnaire - Short Form (IPAQ-Short Form)
Time Frame: baseline
|
baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Mass Index (BMI)
Time Frame: baseline
|
Assessment of body weight status using BMI, calculated as weight in kilograms divided by height in meters squared (kg/m2). |
baseline
|
|
Body Fat Percentage
Time Frame: baseline
|
Evaluation of total body fat composition measured via anthropometric assessment/bioelectrical impedance analysis (BIA). |
baseline
|
|
Waist-to-Hip Ratio (WHR)
Time Frame: baseline
|
Assessment of abdominal obesity calculated as waist circumference divided by hip circumference. |
baseline
|
|
Fasting Blood Glucose
Time Frame: baseline
|
Laboratory evaluation of serum/plasma fasting glucose concentration (mg/dL). |
baseline
|
|
Glycated Hemoglobin (HbA1c)
Time Frame: baseline
|
Laboratory evaluation of glycated hemoglobin level (mmol/mol). |
baseline
|
|
Fasting Serum Insulin
Time Frame: baseline
|
Laboratory evaluation of basal insulin levels micromol/mL. |
baseline
|
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time Frame: baseline
|
index score |
baseline
|
|
Lipid Profile Parameters
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- lipo-diet_2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.